Canterbury DHB

Context

Treatment of AP and BP CML

Choice of treatment of chronic myeloid leukaemia in accelerated and blast crisis should be made by the treating specialist in light of:

Treatment within a clinical trial is preferable.

For previously untreated patients, the 2013 European LeukemiaNet guidelines5 recommend:

Consider alloSCT for fit patients with a high risk for transformation, since the outcome of alloSCT after transformation is unfavourable. Also consider alloSCT early in patients developing AP on a TKI, or high-risk patients with insufficient treatment response.

The only curative option for patients in BP disease is alloSCT. However, for patients considered high risk alloSCT candidates, on-going drug treatment or best supportive care might be the better option.

About this Canterbury DHB document (533105):

Document Owner:

Andrew Butler (see Who's Who)

Issue Date:

August 2018

Next Review:

April 2021

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 533105